secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001062822-24-000057
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon Q3 net loss $64.8M; ZYNQUISTA PDUFA Dec 20 after negative AdCom vote
----------------------------------------------------------------------------

- Net loss $64.8M ($0.18/share) vs $50.5M ($0.21) year ago; revenue $1.8M from INPEFA sales.
- Licensed sotagliflozin to Viatris for ex-U.S./Europe markets; $25M upfront, up to $197M milestones.
- ZYNQUISTA AdCom voted 11-3 that benefits do not outweigh risks; PDUFA target Dec 20, 2024.
- INPEFA net sales $1.7M; field force reduced ~50% in September to focus on targeted prescribers.
- LX9211 Phase 2b DPNP screening complete, topline data now expected Q1 2025; LX9851 IND on track mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282224000057/0001062822-24-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282224000057/lxrx-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001062822-24-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer